Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
One of the three widely awaited clinical trial readouts from Gilead Sciences, Inc. (NASDAQ:GILD) turned out to be a disappointment, sending its shares down sharply Tuesday.
The Analysts
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- Raymond James analyst Steven Seedhouse maintained a Strong Buy rating on Gilead and lowered the price target from $90 to $85.
- Piper Jaffray analyst Tyler Van Buren maintained a Neutral rating and $75 price target.
- Citigroup downgraded Gilead from Buy to Neutral and lowered the price target from $100 to $75.
- Wells Fargo Securities downgraded Gilead from Outperform to Market Perform and reduced the price target from $89 to $68.
RayJay: NASH Trials Doomed, Yet Fundamental Thesis Intact
The data from the STELLAR 3 study in F3 NASH that's due in the second quarter may not be any different, Seedhouse said in a Monday note.
The analyst said he does not expect positive results from the Phase 2 ATLAS combo study of selonsertib plus Gilead's FXR agonist and ACC inhibitor.
RayJay removed NASH from its model despite Gilead's reiteration of its commitment to NASH. Yet Seedhouse said he sees the possibility of a near-term acquisition of a late-stage NASH asset, with Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) being the likely candidate if its REGENERATE study succeeds.
" ... GILD should be much more investable to many and our fundamental thesis (HIV strength, pipeline upside from filgotinib, CAR-T and NASH but now through acquisition only) remains intact," the analyst said.
Piper Jaffray: STELLAR 4 Miss Largely Expected
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Notwithstanding the disappointing STELLAR 4 trial results, there is reason to believe a bigger improvement could be observed in the STELLAR 3 trial due to the less severe population in the study, Van Buren said in a Monday note.
The unofficial 15-percent treatment benefit threshold required to reach statistical significance continues to be a big hurdle, the analyst said.
"We believe this further emphasizes the need for combination therapies to reduce fibrosis, the most important prognostic indicator of cirrhosis and ultimately liver transplant."
Since Piper Jaffray did not include NASH in its model, the sell-side firm maintained its price target for Gilead shares. Moving forward, the firm projects that any success in NASH could lead to upside.
The Price Action
Gilead shares were down 4.61 percent at $64.51 at the time of publication Tuesday.
Related Links:
FDA Panel Reviews Johnson & Johnson's Treatment-Resistant Depression Candidate: What To Expect
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Photo by Nephron/Wikimedia.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.